| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03999216 Details | 2023-04-12 Interventional | 4 | 0 | Diuretics Sodium Chloride… Sodium Potassiu… Heart Failure | Due to administrative and logistical barriers this trial has been withdrawn. - | |||
| NCT03465540 Details | 2023-04-12 Interventional | 1 | 24 | Azacitidine Dexamethasone Hematologic Neo… Leukemia Leukemia, Myelo… Leukemia, Myelo… Multiple Myelom… Myelodysplastic… Preleukemia AML Acute Myeloid L… MDS Myelodysplastic… NHL Non-Hodgkins Ly… | Strategic decisions - | |||
| NCT01805804 Details | 2023-04-12 Interventional | 4 | - | Valsartan Ventricular Rem… First Time Dual… | Recall of some valsartan preparations. 88 patients enrolled and completed the observation. All
patients are in continuous observation and are well. - | |||
| NCT04303559 Details | 2023-04-11 Interventional | 3 | 1 | Antibodies, Bis… Hemophilia A Hemophilia A Wi… | The INHIBIT Trials IDSMB, in a letter dated 05-18-22, recommended, given the slow enrollment,
that the INHIBIT Trials be discontinued due to futility. - | |||
| NCT03729245 Details | 2023-04-11 Interventional | 3 | 623 | Nivolumab Sunitinib Carcinoma Carcinoma, Rena… Metastatic Rena… Renal Cell Carc… | Sponsor decision - | |||
| NCT05492851 Details | 2023-04-10 Interventional | 4 | 6 | Hylan Osteoarthritis Osteoarthritis,… | The study has only enrolled 6 subjects in 6 months since study initiation. Potential
participants are unwilling to participate in the study due to the randomziation and blinding.
Both aspects are needed to ensure a robust comparison between groups. - | |||
| NCT05411575 Details | 2023-04-10 Interventional | 2 | 0 | Plerixafor Acute Lung Inju… COVID-19 Respiratory Dis… Respiratory Dis… Syndrome COVID-19 Acute … | No participants Enrolled - | |||
| NCT04186299 Details | 2023-04-10 Interventional | 4 | 0 | Carticaine Clonidine Epinephrine Pulpitis Symptomatic Irr… | Study activities never commenced. - | |||
| NCT05087771 Details | 2023-04-07 Interventional | 4 | [35 Refs] | 0 | Naltrexone Alcohol Drinkin… Alcoholism Alcohol Use Dis… | no longer randomized, drug being offered to all patients - | ||
| NCT04817345 Details | 2023-04-07 Interventional | 2 | 0 | Plerixafor Anemia, Sickle … Sickle Cell Dis… | The safety and efficacy of plerixafor in adult and pediatric SCD patients was an unknown when
we started. A lot more data from therapeutic trials is available. We feel that recruiting
patients without a therapeutic option isn't ethically justifiable. - | |||
| NCT04422795 Details | 2023-04-07 Interventional | 4 | 0 | Ethyl Chloride Nail Diseases | Due to reallocation of resources, this study could not be initiated - | |||
| NCT03867500 Details | 2023-04-07 Interventional | 1 | - | Niacin Diabetes Mellit… Diabetes Mellit… Obesity Type 2 Diabetes… | Study halted prematurely but potentially will resume. - | |||
| NCT03301896 Details | 2023-04-07 Interventional | 1 | 45 | Spartalizumab Neoplasms Solid Tumors | Business reasons - | |||
| NCT05215951 Details | 2023-04-06 Interventional | 2 | 5 | Osimertinib Lung Neoplasms Lung Cancer | Enrollment delay study timeline seriously. - | |||
| NCT03642132 2017-004456-30 Details | 2023-04-06 Interventional | 3 | 79 | Avelumab Bevacizumab Talazoparib Carcinoma, Ovar… Ovarian Neoplas… Ovarian Cancer | Phase 3 B9991010 study was stopped due to futility of efficacy at interim analysis on
21Dec2018, and approvals of PARP inhibitors in front-line maintenance setting, Pfizer decided
stopping enrollment in the B9991030 study on 19Mar2019. As of 19 March 2019, the sponsor decided to stop enrollment/randomization in the study. A total of 104 participants were screened and 79 participants completed screening and randomized in the study before study discontinuation. As only 11% projected enrollment was met at the time of enrollment stop, the original study endpoints are no longer applicable and/or feasible; only the Safety, PK and Immunogenicity Analysis were done and these data are included in this report. | |||
| NCT05668936 2022-002479-12 Details | 2023-04-05 Interventional | 1 | 31 | Moxifloxacin Norgestimate, e… Fatty Liver Non-alcoholic F… Non-alcoholic S… | Discontinuing the development of cotadutide, a daily injectable GLP-1/glucagon co-agonist, is
based on strategic pipeline considerations. The premature closure is not due to any newly
observed safety signals or a change in the risk/benefit profile. - | |||
| NCT02927249 Details | 2023-04-05 Interventional | 3 | 3021 | Aspirin Breast Neoplasm… Node Positive H… | DSMB review - | |||
| NCT02890368 Details | 2023-04-05 Interventional | 1 | 56 | Immune Checkpoi… Immunoglobulin … Interferons Talimogene lahe… Breast Neoplasm… Carcinoma Carcinoma, Merk… Mycoses Mycosis Fungoid… Sarcoma Breast Carcinom… Human Papilloma… Melanoma Merkel-cell Car… Soft Tissue Sar… Solid Tumors Squamous Cell C… | - - | |||
| NCT04354025 Details | 2023-04-04 Interventional | 2 | 0 | Cytarabine Fludarabine Interleukin-2 Leukemia Leukemia, Myelo… Leukemia, Myelo… Refractory Acut… Relapsed Acute … | Principal investigator decided not to move forward with the study. - | |||
| NCT01332279 Details | 2023-04-04 Interventional | 1 | 0 | Erlotinib Hydro… Everolimus Carcinoma Carcinoma, Squa… Carcinoma, Verr… Head and Neck N… Laryngeal Disea… Laryngeal Neopl… Recurrence Salivary Gland … Squamous Cell C… Tongue Neoplasm… Recurrent Metas… Recurrent Saliv… Recurrent Squam… Recurrent Squam… Recurrent Squam… Recurrent Squam… Recurrent Squam… Recurrent Verru… Recurrent Verru… Salivary Gland … Tongue Cancer | Pharmaceutical co. withdrew support. Study was never activated and did not accrue any patients. - |